Atom Investors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Atom Investors’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-139,422	Closed	-$1.68M	–	654
2025 Q4	$1.68M	Buy	+139,422	New	+$1.89M	0.13%	229
2024 Q2	–	Sell	-189,796	Closed	-$539K	–	476
2024 Q1	$539K	Buy	+189,796	New	+$2.48M	0.07%	320
2022 Q2	–	Sell	-36,691	Closed	-$471K	–	252
2022 Q1	$471K	Buy	+36,691	New	+$829K	0.22%	105

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Atom Investors's AMLX Position: Q1 2026 in Review

Atom Investors sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 139,422 shares — an estimated $1.68M sold.

Atom Investors first reported a position in AMLX in Q1 2022 and held it in 3 quarters. The position peaked at $1.68M in Q4 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Atom Investors reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Atom Investors sold 139,422 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $1.68M.
Atom Investors first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 3 quarters.
Atom Investors's Amylyx Pharmaceuticals position peaked at $1.68M in Q4 2025.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.